Meeting
2016 ASCO Annual Meeting
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.
Authors
Mark Agulnik
Northwestern University, Feinberg School of Medicine, Chicago, IL
Mark Agulnik , Nizar M. Tannir , Joseph Gerald Pressey , Mrinal M. Gounder , Gregory Michael Cote , Maria Roche , Susan Doleman , Stephen J Blakemore , Alicia Clawson , Scott Daigle , Jeanie Tang , Peter T.C. Ho , George D. Demetri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02601950
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS11071)
DOI
10.1200/JCO.2016.34.15_suppl.TPS11071
Abstract #
TPS11071
Poster Bd #
196b
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma.
First Author: Susan N. Chi
Poster
2024 ASCO Annual Meeting
TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors.
First Author: Joanna S. Yi
Poster
2022 ASCO Annual Meeting
Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C).
First Author: Susan N. Chi
Poster
2017 ASCO Annual Meeting
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950).
First Author: Patrick Schoffski